267 related articles for article (PubMed ID: 11422206)
21. Immunopathogenesis of inflammatory myopathies.
Dalakas MC
Ann Neurol; 1995 May; 37 Suppl 1():S74-86. PubMed ID: 8968219
[TBL] [Abstract][Full Text] [Related]
22. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis.
Sugihara T; Sekine C; Nakae T; Kohyama K; Harigai M; Iwakura Y; Matsumoto Y; Miyasaka N; Kohsaka H
Arthritis Rheum; 2007 Apr; 56(4):1304-14. PubMed ID: 17394136
[TBL] [Abstract][Full Text] [Related]
23. Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins.
Appeltshauser L; Weishaupt A; Sommer C; Doppler K
Exp Neurol; 2017 Jan; 287(Pt 1):84-90. PubMed ID: 27746185
[TBL] [Abstract][Full Text] [Related]
24. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg").
Stangel M; Compston A; Scolding NJ
J Neuroimmunol; 2000 Mar; 103(2):195-201. PubMed ID: 10696915
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
Dalakas MC
Clin Rev Allergy Immunol; 2005 Dec; 29(3):255-69. PubMed ID: 16391401
[TBL] [Abstract][Full Text] [Related]
26. High-dose intravenous immunoglobulin treatment activates complement in vivo.
Mollnes TE; Høgåsen K; De Carolis C; Vaquero E; Nielsen EW; Fontana L; Perricone R
Scand J Immunol; 1998 Sep; 48(3):312-7. PubMed ID: 9743219
[TBL] [Abstract][Full Text] [Related]
27. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level.
Lutz HU; Stammler P; Bianchi V; Trüeb RM; Hunziker T; Burger R; Jelezarova E; Späth PJ
Blood; 2004 Jan; 103(2):465-72. PubMed ID: 14512320
[TBL] [Abstract][Full Text] [Related]
28. Adhesion molecule expression in experimental myositis.
Ito T; Kumamoto T; Horinouchi H; Yukishige K; Sugihara R; Fujimoto S; Tsuda T
Muscle Nerve; 2002 Mar; 25(3):409-18. PubMed ID: 11870719
[TBL] [Abstract][Full Text] [Related]
29. C-protein in the skeletal muscle induces severe autoimmune polymyositis in Lewis rats.
Kohyama K; Matsumoto Y
J Neuroimmunol; 1999 Aug; 98(2):130-5. PubMed ID: 10430046
[TBL] [Abstract][Full Text] [Related]
30. Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.
Quast I; Keller CW; Weber P; Schneider C; von Gunten S; Lünemann JD
J Neuroinflammation; 2016 Feb; 13():42. PubMed ID: 26893156
[TBL] [Abstract][Full Text] [Related]
31. From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.
Patel SY; Kumararatne DS
Clin Exp Immunol; 2001 May; 124(2):169-71. PubMed ID: 11422191
[No Abstract] [Full Text] [Related]
32. Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury.
Dantas M; Costa RS; Barbosa JE; Graeff MS; Sarti W; De Carvalho IF
Clin Exp Immunol; 2000 Jul; 121(1):139-45. PubMed ID: 10886251
[TBL] [Abstract][Full Text] [Related]
33. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance.
Basta M; Langlois PF; Marques M; Frank MM; Fries LF
Blood; 1989 Jul; 74(1):326-33. PubMed ID: 2752117
[TBL] [Abstract][Full Text] [Related]
34. High dose intravenous immunoglobulin does not affect complement-bacteria interactions.
Wagner E; Platt JL; Frank MM
J Immunol; 1998 Feb; 160(4):1936-43. PubMed ID: 9469456
[TBL] [Abstract][Full Text] [Related]
35. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy.
Yuki N; Watanabe H; Nakajima T; Späth PJ
J Neurol Neurosurg Psychiatry; 2011 Jan; 82(1):87-91. PubMed ID: 20667861
[TBL] [Abstract][Full Text] [Related]
36. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway.
Basta M; Fries LF; Frank MM
Blood; 1991 Aug; 78(3):700-2. PubMed ID: 1859883
[TBL] [Abstract][Full Text] [Related]
37. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I
J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
Dalakas MC
JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
[TBL] [Abstract][Full Text] [Related]
39. Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition.
Sudo M; Yamaguchi Y; Späth PJ; Matsumoto-Morita K; Ong BK; Shahrizaila N; Yuki N
PLoS One; 2014; 9(9):e107772. PubMed ID: 25259950
[TBL] [Abstract][Full Text] [Related]
40. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
Dalakas MC
Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
